Action - PRAN

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

2,0597

Prix Achat

1,98

Prix Vente

2,10

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

2,0597

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA...

Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana

Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana PR Newswire MELBOURNE, Australia and SAN...

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model...

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today...

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence supports activity...

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Highlights: Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment...

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture Prana Biotechnology...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

PRAN - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 2,0597

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
VRMVroom Inc	US$ 24,50 (390,00%)	114
STECSantech Holdings Limited	US$ 2,91 (347,49%)	52,18M
RETOReTo Eco Solutions Inc	US$ 1,05 (158,68%)	21,98M
LINKInterlink Electronics Inc	US$ 13,00 (84,40%)	298
ORISOriental Rise Holdings Ltd	US$ 1,95 (74,11%)	16,02M
PHVSPharvaris NV	US$ 10,01 (-39,30%)	13
EBMTEagle Bancorp Montana Inc	US$ 12,01 (-33,35%)	22
THTarget Hospitality Corporation	US$ 6,57 (-29,81%)	39,49k
BOXLBoxlight Corporation	US$ 2,34 (-24,52%)	31,56k
WDCWestern Digital Corporation	US$ 52,84 (-23,09%)	8,12k
STECSantech Holdings Limited	US$ 2,91 (347,49%)	52,18M
CNEYCN Energy Group Inc	US$ 0,3587 (46,65%)	38,01M
RETOReTo Eco Solutions Inc	US$ 1,05 (158,68%)	21,98M
ORISOriental Rise Holdings Ltd	US$ 1,95 (74,11%)	16,02M
ADTXAditxt Inc	US$ 0,0829 (-9,40%)	15,6M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Prana Biotechnology Ltd ADS (PRAN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

PRAN Dernières nouvelles

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

PRAN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Prana Biotechnology Ltd ADS (PRAN) Cours

Prana Biotechnology Ltd ADS (PRAN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

PRAN Dernières nouvelles

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

PRAN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS